DOCS

DOXIMITY INC

Healthcare | Mid Cap

$0.20

EPS Forecast

$175.6

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Doximity’s Q1FY2027: AI Engagement Rises, but Margins Take a Detour (DOCS)

For DOCS, the Nyse-listed healthcare professional network, the first quarter of fiscal 2027 shows the stock’s familiar trade: revenue climbs, engagement expands, and profitability exercises a little house-keeping. In plain terms, Doximity reported revenue of $156.6 million, up 7% year over year, with Diluted EPS of $0.13 and non‑GAAP EPS of $0.29. In the same breath, margins softened: GAAP net income of $24.3 million and net income margin of about 15.5% contrast with prior-year margins of 36.5% on GAAP and 49.2% non‑GAAP for the quarterly baseline. Adjusted EBITDA came in at $74.8 million, a 47.7% margin, down from 54.7% a year earlier. The press release is littered with the kind of arithmetic that makes investors lean toward the model — the revenue forecast, the EPS figures, and the implied consistency (or lack thereof) with EPS consensus — but the obvious story is growth via AI-enabled product engagement, not margin expansion. SEO notes: DOCS, EPS, earnings surprise, EPS consensus, revenue forecast, revenue, EBITDA margin.

Quarterly snapshot

  • Revenue: $156.6 million, up 7% year over year.
  • Net income (GAAP): $24.3 million, margin 15.5% (vs. 36.5% in the prior year period).
  • Non-GAAP net income: $55.0 million, margin 35.1% (vs. 49.2%).
  • Adjusted EBITDA: $74.8 million, margin 47.7% (vs. 54.7%).
  • Earnings per share (diluted): $0.13, vs. $0.27 a year ago; non-GAAP diluted EPS: $0.29, vs. $0.36.
  • Cash flow: Operating cash flow $42.0 million; free cash flow $39.6 million (down 32% and 34% year over year, respectively).

Guidance and what it portends

The company guides for the second quarter ending September 30, 2026 to revenue between $170 million and $171 million, and adjusted EBITDA between $80.5 million and $81.5 million. For the full year ending March 31, 2027, Doximity expects revenue in a range of $671 million to $681 million and adjusted EBITDA in a range of $309 million to $329 million.

Translation, if you want one: topline momentum should persist, but the operating leverage story remains a work in progress. The growth runway is visible in engagement metrics—Doximity says its clinical AI assistant, Doximity Ask, performed prominently in benchmarks, with AI Search queries up more than 25% quarter over quarter. Yet that incremental growth comes with margin headwinds and heavier investment that keeps GAAP profitability under pressure even as non‑GAAP measures look steadier.

What this means for DOCS and sector peers

The first-quarter print reads like a company that has found a bigger, more ambitious user engagement channel in AI, while fighting the math of cost and investment. Revenue growth is respectable at a mid‑single‑digit pace in the context of a high‑growth software-driven health tech company, but the margin compression—especially on GAAP bases and even on adjusted EBITDA—suggests ongoing investment in platform development and go‑to‑market expansion.

The juxtaposition of a 7% revenue lift with a 32% drop in operating cash flow signals that the near-term cash cadence is being set by product investment and operating costs, not merely by revenue timing. For investors, the key question remains: will AI-enabled features translate into durable monetization and improved unit economics as the platform scales? The company’s guidance hints at continued growth but with margins that may lag the best‑case profitability story for the sector.

For sector peers, the message is nuanced. If engagement-driven monetization via AI features can lift activity without exploding cost structures, the lane for software-enabled healthcare networks could widen. But if R&D and go‑to‑market spend continue to outpace incremental revenue, the comparison across the space will tighten around gross margins and free cash flow generation, not just raw revenue growth.

Takeaways for investors and analysts

  • The ticker DOCS remains a proxy for growth in physician-facing software ecosystems, with AI-enabled features acting as a differentiator in a crowded field.
  • The EPS story is mixed: diluted GAAP EPS of $0.13 is materially down versus the prior year, while EPS consensus benchmarks may look for stabilization or a path to improvement through operating leverage and margin recovery.
  • The earnings surprise angle is unclear from this release; investors will want to see how the quarterly figures stack up against Street expectations once published, particularly on the non‑GAAP line where management highlights a stronger margin profile.
  • Watching the revenue forecast for the next quarters is critical. The Q2 range and the full-year outlook imply continued momentum, but the degree to which AI-driven engagement translates into sustainable profitability will define multiple expansions or contractions in the near term.
  • In the broader sector, peers will be assessing whether higher engagement metrics (like AI usage) can be monetized more efficiently or if costs rise faster than revenue, a classic test of growth versus profitability in enterprise software with healthcare‑specific tailwinds.

Closing thought

Doximity’s quarter is not a reversal of fortune, but a calibration: growth is real, AI-driven usage is visible, and profitability remains a work in progress. In Matt Levine fashion, the takeaway is simple enough to articulate and complex enough to watch: if the platform can convert engagement into durable cash flow, the fertility of the DOCS thesis remains intact; if not, the same AI spark that dazzled the quarterly press release could burn off the burn rate without a corresponding uptick in per-user value. Until then, the market will parse EPS, revenue forecast revisions, and the cadence of cash flow as the metronome for DOCS and its health-tech peers.